Celltrion anticipates Trump admin will bring positive shift

By Whang, byung-woo | translator Hong, Ji Yeon

24.11.14 05:35:49

가나다라 0

Changes such as a policy promoting generic and biosimilar uses are anticipated

The 'Biosecure Act' will drive Celltrion's CDMO business, its future growth momentum

Celltrion "An opportunity to focus mainly on business aspects, marketing expansion and sales growth"

Celltrion anticipates that President-elect Donald Trump's second administration in the United States will positively affect the company's biosimilars and Contract Development and Management Operations (CDMO) services.

On November 12, Celltrion presented stockholders with the potential impact on the business under the title 'The Business Impact and Outlook upon President-elect Donald Trump's second administration in the United States launches.'

Celltrion cited a report from the Korea Institute for Industrial Economics and Trade, 'The potential impacts of the U.S. presidential election on Korean industry and outlook,' and analyzed that the Trump administration will be friendly towards using

Whang, byung-woo(tuai@dailypharm.com)

If you want to see the full article, please JOIN US (click)